Deregulation of purine pathway in Bacillus subtilis and its use in riboflavin biosynthesis
© Shi et al.; licensee BioMed Central 2014
Received: 14 April 2014
Accepted: 6 July 2014
Published: 15 July 2014
Purine nucleotides are essential metabolites for living organisms because they are involved in many important processes, such as nucleic acid synthesis, energy supply, and biosynthesis of several amino acids and riboflavin. Owing to the pivotal roles of purines in cell physiology, the pool of intracellular purine nucleotides must be maintained under strict control, and hence the de novo purine biosynthetic pathway is tightly regulated by transcription repression and inhibition mechanism. Deregulation of purine pathway is essential for this pathway engineering in Bacillus subtilis.
Deregulation of purine pathway was attempted to improve purine nucleotides supply, based on a riboflavin producer B. subtilis strain with modification of its rib operon. To eliminate transcription repression, the pur operon repressor PurR and the 5’-UTR of pur operon containing a guanine-sensing riboswitch were disrupted. Quantitative RT-PCR analysis revealed that the relative transcription levels of purine genes were up-regulated about 380 times. Furthermore, site-directed mutagenesis was successfully introduced into PRPP amidotransferase (encoded by purF) to remove feedback inhibition by homologous alignment and analysis. Overexpression of the novel mutant PurF (D293V, K316Q and S400W) significantly increased PRPP amidotransferase activity and triggered a strong refractory effect on purine nucleotides mediated inhibition. Intracellular metabolite target analysis indicated that the purine nucleotides supply in engineered strains was facilitated by a stepwise gene-targeted deregulation. With these genetic manipulations, we managed to enhance the metabolic flow through purine pathway and consequently increased riboflavin production 3-fold (826.52 mg/L) in the purF-VQW mutant strain.
A sequential optimization strategy was applied to deregulate the rib operon and purine pathway of B. subtilis to create genetic diversities and to improve riboflavin production. Based on the deregulation of purine pathway at transcription and metabolic levels, an extended application is recommended for the yield of products, like inosine, guanosine, adenosine and folate which are directly stemming from purine pathway in B. subtilis.
Purine nucleotides are essential metabolites for cellular physiology because they are structural components of both DNA and RNA, energy carriers (i.e. ATP and GTP) and enzyme cofactors (i.e. NAD+ and NADP+). In addition, purine nucleotides are involved in many important anabolic pathways for biosynthesis of several amino acids and vitamins such as folic acid and riboflavin, which are of significant economic interest for the biotechnology industry [1-3].
The de novo purine biosynthetic pathway is nearly ubiquitous and leads the conversion of PRPP and glutamine into IMP through 10 different enzymatic reactions, after which IMP can be transformed into AMP or GMP in two additional steps. Alternatively, purines can also be transformed directly to their nucleoside monophosphate derivatives using the intracellular pool of PRPP for recycling of nucleobases through the salvage pathways . Owing to the pivotal roles of purines in cell physiology, the pool of intracellular purine nucleotides must be maintained under strict control, and hence the de novo purine biosynthetic pathway is tightly regulated by transcription repression and inhibition mechanism .
Regarding feedback inhibition mechanism, enzyme activities are subjected to end product-feedback inhibition in purine pathway of B. subtilis, e.g. PRPP synthetase, PRPP amidotransferase, adenylsuccinate synthetase and IMP dehydrogenase [5,14] (Figure 1B). PRPP amidotransferase, encoded by purF, catalyzes the initial reaction of purine pathway and is the key regulatory enzyme in this pathway. Expression of purF is repressed at transcriptional level by extracellular purines , and the activity of PRPP amidotransferase is rigorously regulated by feedback inhibition through the specific binding of adenine and guanine nucleotides . As reported, the structural features of B. subtilis PRPP amidotransferase have been described, and several mutated residues (S283A, K305Q, R307Q and S347A) were successfully introduced into PRPP amidotransferase to release it from feedback regulation . The inhibitory properties of PRPP amidotransferase in other strains such as E. coli and Ashbya gossypii were also abolished by site-directed mutagenesis [16-18]. For example, overexpression of the desensitized PurF (K326Q and P410W) significantly redirected carbon flow through the de novo purine biosynthetic pathway in inosine-producing strain E. coli W3110 . Jiménez et al  had introduced residue mutations (D310V, K333Q and A417W) into PRPP amidotransferase (encoded by AgADE4) in A. gossypii, and the mutated AgADE4 was overexpressed to abolish the adenine-mediated transcription repression and to reduce sensitivity against inhibition by ATP and GTP. Similarly, new residue mutations of B. subtilis PRPP amidotransferase are explored to release feedback inhibition and to direct the metabolic flux of purine pathway, which are of importance for the yield of products directly stemming from purine pathway in B. subtilis.
As mentioned above, the purine biosynthetic network is closely connected to many important metabolic pathways for biotechnology application. B. subtilis has a long tradition as safe and stable producer for purine nucleotides [13,20,21]. It should be noted that B. subtilis has constituted a paradigm of environmentally friendly “white” biotechnology with regard to industrial riboflavin overproduction [22,23]. Riboflavin is an important extensive research compound, since it serves as a precursor of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), and is also an essential nutrient for humans and animals as food additive . For biosynthesis of riboflavin in B. subtilis, poor availability of purine nucleotides may limit the precursor GTP supply. Genetic manipulation of the de novo purine biosynthetic pathway in B. subtilis could considerably enhance the production of riboflavin.
In this work, we tried to engineer the rib operon in a riboflavin producer B. subtilis strain to direct necessary high levels of carbon flow through the riboflavin biosynthetic pathway, including overexpression of the key gene (ribA), substitution the native promoter ribP1 with strong promoter P 43 and disruption of the RFN regulatory region ribO. Afterwards, a sequential optimization strategy was applied to deregulate purine pathway in the rib operon manipulated B. subtilis mutant strain. The repressor PurR and the 5’-UTR of pur operon containing a guanine-sensing riboswitch were both disrupted to eliminate transcription repression. And quantitative RT-PCR analysis revealed that the relative transcription levels of purine genes were up-regulated. Site-directed mutagenesis was subsequently introduced into PRPP amidotransferase to remove feedback inhibition by homologous alignment and analysis. The characteristics of mutant PRPP amidotransferase were analyzed, and intracellular metabolite profile changes of different engineered strains confirmed significant deregulation of purine pathway. With these manipulations, we managed to enhance the metabolic flow through purine pathway and consequently increased riboflavin production 3-fold (826.52 mg/L) in the purF-VQW mutant strain.
Genetic manipulation of the B. subtilis rib operon for riboflavin production
In order to direct the necessary high levels of carbon flow through the riboflavin biosynthetic pathway in B. subtilis, we attempted to engineer the rib operon in riboflavin producer strain BS77 that contained mutations in regulatory gene ribC and RFN regulatory element ribO (unpublished work). The strong constitutive promoter P 43 derived from B. subtilis 168 was firstly inserted into upstream of ribA in BS77 to generate mutant strain BS89. Subsequently, the rib operon was constitutively overexpressed in mutant strain BS89 by either replacing the native promoter ribP1 and ribO with strong promoter P 43 or by deleting ribO, resulting in mutant strains BS93 and BS96, respectively.
Metabolic characterizations of B. subtilis strains in minimal medium supplemented with 20 g/L glucose
Specific growth rate (h-1)
0.66 ± 0.01
0.64 ± 0.00
0.59 ± 0.01
0.62 ± 0.00
0.61 ± 0.01
0.61 ± 0.01
0.56 ± 0.01
0.60 ± 0.01
0.55 ± 0.01
0.45 ± 0.01
0.64 ± 0.04
Specific riboflavin production rate (μmol•g-1CDW•h-1)
32.85 ± 2.66
41.65 ± 1.51
30.80 ± 2.72
6.52 ± 1.79
32.74 ± 1.81
35.10 ± 1.21
34.96 ± 1.58
51.46 ± 3.58
27.15 ± 2.04
32.79 ± 0.48
61.15 ± 0.85
Specific glucose uptake rate (mmol•g-1CDW•h-1)
18.82 ± 2.08
16.25 ± 0.96
17.02 ± 1.02
19.45 ± 1.54
16.13 ± 0.13
17.35 ± 1.06
14.33 ± 0.26
15.38 ± 0.39
12.35 ± 0.54
8.69 ± 0.19
18.94 ± 3.00
Riboflavin yield (mg/g glucose)
2.10 ± 0.02
5.02 ± 0.06
4.26 ± 0.20
1.10 ± 0.04
5.21 ± 0.07
4.97 ± 0.14
5.56 ± 0.45
6.55 ± 0.50
5.12 ± 0.05
8.46 ± 0.30
5.84 ± 0.04
The relative transcription levels of rib genes (ribG and ribA) were measured in different mutant strains by quantitative RT-PCR (Figure 2B). The relative transcription levels of ribG and ribA in mutant BS89 were significantly enhanced by approximately 2-fold higher than that of BS77. These results convincingly demonstrated that ribA overexpression could raise the metabolic flux of rate-limiting step, reflecting its direct contribution on riboflavin overproducing phenotype. Whereas the relative transcription levels of ribG and ribA in BS93 and BS96, constitutive expression of rib operon based on BS89, were decreased drastically, indicating that ribO disruption was probably the main reason for riboflavin yield drawdown. Therefore, mutant BS89 was used as the original strain to be manipulated for deregulating the de novo purine biosynthetic pathway through comprehensive analysis.
Deregulation of purine pathway for enhancement of transcription levels
A sequential deregulation strategy was applied to elevate the transcription levels of purine pathway. The purR gene was disrupted to eliminate the transcription repression on purine pathway. Meanwhile, the original -10 sequence (TAAGAT) of Ppur (the pur operon promoter region) and the 5’-UTR of pur operon containing a guanine-sensing riboswitch were both engineered to increase the pur operon promoter activity.
For improving the pur operon promoter activity, the original -10 sequence (TAAGAT) of Ppur in BS102 was mutated with frequently used -10 sequence (TATAAT) in B. subtilis  to generate mutant strain BS103 (-10*). A 75-bp region which was defined as att corresponding to the attenuator region in 5’-UTP  was also deleted, leading to mutant strains BS104 (Δatt) based on BS102 and BS107 (-10*, Δatt) based on BS103, respectively. In comparison with the riboflavin production of 529.54 ± 5.29 mg/L in BS102, it was drastically enhanced to 627.15 ± 20.61 mg/L in Δatt mutant strain BS104, and less enhanced to 581.46 ± 8.34 mg/L in the combination of -10* and Δatt mutant strain BS107, but almost unchanged in -10* mutant strain BS103 (507.74 ± 15.33 mg/L) (Figure 3B). Noticeably, from the point of relative transcription levels, the att deletion was also efficacious for pur operon deregulation. As shown in Figure 3A, it presented the highest relative transcription levels of purE and purF than other mutant strains. Meanwhile, the relative transcription levels of guaC and purA were declined to some extent by this deregulation manipulation of att deletion, which was in favor of the accumulation of riboflavin. Physiological parameters and riboflavin production indicated att deletion played a vital role in improving the pur operon promoter activity, while the -10* point mutation failed to take effect.
Identification of the residue mutations for PurF to release PRPP amidotransferase from feedback regulation
To deregulate the committed step encoded by purF in purine pathway, a series of mutants were constructed. The wild-type purF in BS104 was firstly overexpressed, via inserting a strong promoter P 43 upstream of purF, to generate mutant strain BS106. Then, the three residue mutations (D293V, K316Q and S400W) were introduced into BS106 to yield mutant strain BS110 with purF-VQW mutation module. Besides, mutated purF gene from E. coli containing mutations K326Q and P410W was successfully introduced into strain BS106 using plasmid pSS-purF*(eco)-FB to replace the wild-type purF, which was named BS111.
Influence of purF mutant expression on riboflavin production and metabolic characteristics
Concentrations of purine intermediates [μmol g CDW -1 ] determined for B. subtilis mutants
Concentration [μmol g CDW -1 ]
0.032 ± 0.006
0.042 ± 0.003
0.054 ± 0.007
0.054 ± 0.009
0.04 ± 0.011
0.066 ± 0.017
0.066 ± 0.013
0.024 ± 0.001
1.13 ± 0.12
3.62 ± 0.22
2.53 ± 0.24
3.58 ± 0.43
3.74 ± 0.58
4.31 ± 0.34
3.79 ± 0.27
2.26 ± 0.28
14.36 ± 2.13
32.45 ± 3.18
15.35 ± 1.25
29.82 ± 3.12
48.12 ± 3.53
47.96 ± 3.19
25.00 ± 3.01
4.80 ± 0.29
0.15 ± 0.011
0.16 ± 0.013
0.079 ± 0.005
0.14 ± 0.017
0.24 ± 0.031
0.26 ± 0.018
0.12 ± 0.017
0.024 ± 0.019
0.02 ± 0.002
0.027 ± 0.007
0.028 ± 0.005
0.011 ± 0.009
0.021 ± 0.003
0.04 ± 0.007
0.011 ± 0.003
0.004 ± 0.002
2.37 ± 0.16
9.25 ± 1.11
4.20 ± 0.55
9.36 ± 0.87
4.63 ± 0.28
1.80 ± 0.13
9.42 ± 1.12
3.45 ± 0.35
0.17 ± 0.012
0.19 ± 0.011
0.14 ± 0.005
0.41 ± 0.032
0.22 ± 0.019
0.42 ± 0.035
0.35 ± 0.043
0.13 ± 0.015
0.044 ± 0.012
0.056 ± 0.016
0.039 ± 0.009
0.067 ± 0.011
0.046 ± 0.014
0.047 ± 0.009
0.062 ± 0.017
0.024 ± 0.012
Engineered forms of PRPP amidotransferase were metabolically deregulated
With respect to enzyme activity, significant changes for PRPP amidotransferase were observed in different mutant strains including BS104, BS106, BS110 and BS111. As shown in Figure 5B, the enzyme activity in BS106 was increased by 23% compared to the control strain BS104, indicating that overexpression of purF gene under strong promoter P 43 was an effective means for improving the PRPP amidotransferase activity. Moreover, significant enhancement of PRPP amidotransferase activity in BS110 containing purF-VQW was observed, which was 1.63 times higher than that of BS106 and 2 times higher than that of BS104. It could be explained that residue modifications in the active centers frequently resulted in a drastic alteration in enzyme characteristics. To our surprise, substitution of the B. subtilis purF gene by the mutated purF gene from E. coli in BS111 failed to enhance enzyme activity and, on the contrary, the enzyme activity had a slight reduction. In the present work, the same promoter P 43 and ribosome binding site were used to control the expression of purF or its derivations derived from B. subtilis or E. coli. So the different phenotypes of mutant purF should not be attributed to the control elements of promoter or ribosome binding site for gene expression. Further investigation was carried out to test whether there were rare codons existed in mutant purF from E. coli. The results exhibited that 21 rare codons were used less than 10% for heterologous expression in B. subtilis. Rare codons can reduce the efficiency of translation or even disengage the translational machinery [25-28]. Taking the above mentioned into consideration, the low expression of mutant purF derived from E. coli failed to enhance the enzyme activity.
Intracellular metabolite target analysis confirmed significant deregulation of purine pathway
Intracellular metabolite target analysis was a good option for detecting the genetic modification effects, as observed realities suggested that a change in the activity of single enzyme-often the result of genetic modification, usually produced a larger signal in the metabolite concentrations than in the metabolic fluxes . In this study, to gain further insight into the deregulation of purine pathway for riboflavin biosynthesis, major changes of intracellular purine nucleotide concentrations were evaluated in these mutant strains. The metabolite concentrations with significant differences among mutant strains were listed in Table 2.
The intermediates of purine pathway such as IMP, AMP, GMP and GTP were higher in purR disruption mutant BS102 compared with parent strain BS89. It might because the defective PurR deregulated purine pathway so as to up-regulate the relative transcription levels of purine genes and then enhanced the intermediate pools. The related purine nucleotides concentrations in BS104 containing att deletion based on BS102 had some variation. The intermediates of AMP, ADP and ATP in the branch pathway for ATP formation were slightly decreased, and that of GMP, GDP and GTP had a certain degree of improvement. From these data, it could be concluded that the enhanced supply of intracellular guanine nucleotides was consistent with the enhancement of riboflavin production in mutant strains BS102 and BS104. The significant deregulation of purine pathway at transcriptional level, facilitated by the stepwise gene-targeted manipulations, was supposed to be the major reason for improvement of both intermediate pools and riboflavin biosynthesis flux.
Moreover, major changes of intermediate purine nucleotide concentrations in different engineered purF mutant strains were detected. Table 2 showed that overexpression purF in BS106 decreased the concentrations of GMP, GDP and GTP but increased that of AMP, ADP and ATP in contrast with BS104. In addition, inserting purF-VQW mutations into BS106 leading to BS110 actually enhanced the concentrations of GMP, GDP and GTP compared with BS106, which showed an activation of purine pathway for riboflavin biosynthesis precursor GTP supply.
In this work, to test the deregulation validity of the de novo purine biosynthetic pathway for riboflavin overproduction, genetic manipulations of rib operon were previously applied to direct the necessary high levels of carbon flow through the riboflavin biosynthetic pathway in B. subtilis. We tried three different ways to further deregulate the rib operon by overexpression of the key gene (ribA), substitution the native promoter ribP1 and the RFN regulatory region ribO with strong promoter P 43 and disruption of ribO in a riboflavin producer B. subtilis strain containing ribC and ribO mutations. It was surprising that such high relative transcription levels of rib genes (ribG and ribA) were achieved by only overexpression of the key gene ribA without modification of the native promoter ribP1 and the RFN regulatory region. As Humbelin et al  reported, a further increase in riboflavin titer was observed when a single copy of constitutively expressed ribA was introduced into B. subtilis strain RB50::[pRF69]n::[pRF93]m. Similar results enabled us to conclude that the metabolic flux of rate-limiting step catalyzed by ribA played an important role in riboflavin biosynthesis. Furthermore, Mironov et al  reported deletion of the main leader region of rib operon encoding FMN-specific sensor RNA in B. subtilis affected riboflavin production. In our study, ribO deletion seriously affected the transcription levels of rib genes (ribG and ribA) and made riboflavin yield decreased. Our results indicated that some additional FMN-dependent regulation was involved in rib operon control, which is, however, still connected with the primary and secondary structure of the leader region.
Genetic manipulations on the de novo purine biosynthetic pathway were applied to enhance the transcription levels of purine genes. In this study, purR deletion in strain BS102 elevated the relative transcription levels of seven key purine genes involved in purine metabolism. Even the relative transcription levels of purE and purF were up to 30 times and purA and guaC were up to 100 times. The Δatt mutation based on BS102 was also effective, with the relative transcription levels of purE and purF were further enhanced and guaC and purA were declined. The purR deletion and Δatt mutation were both advantageous to the deregulation of purine pathway, reflecting that the riboflavin production was increased from 506.45 ± 3.50 mg/L to 627.15 ± 20.61 mg/L. Asahara et al  performed gene targeted mutagenesis to construct inosine-producing B. subtilis with an enhanced pur operon expression, which including purR and att inactivation and the original -10 sequence (TAAGAT) of Ppur mutation. The effects of purR and att inactivation were consistent with our experimental results for the enhanced relative transcription levels of purine genes. The -10 mutation was effective in the increase of inosine, but it presented little effect on enhancement of the riboflavin production in our study.
As a tightly regulated pathway, purine biosynthesis is rigorously regulated at transcription and metabolic levels . The committed step of pathway, the formation of PRA, seems to be critical . To deregulate the formation of PRA at both transcription and metabolic levels, we firstly inserted a strong promoter P 43 at the purF locus in BS104 to generate mutant BS106 for co-overexpression of the purF, purM, purN, purH, purD genes in pur operon. Better performances were exhibited in mutant BS106 with high levels of PRPP amidotransferase activity and improved riboflavin production. But overexpression of purF in BS106 was not enough to increase the production of riboflavin up to biotechnologically significant level, because wild-type PRPP amidotransferase was still endured intense feedback inhibition of all four purine nucleotides (AMP, ATP, GMP and GTP) (Figure 6). We then mutated three residues of PRPP amidotransferase that were homologous to those reported to be essential for purine nucleotides binding in E. coli [16,17]. Intriguingly, the purF-VQW mutations in BS110 led an important increase in riboflavin production, whereas caused growth delay (from 0.60 ± 0.01 h-1 to 0.45 ± 0.01 h-1). The reason for this discrepancy might be related to the metabolic imbalance of purine pathway caused by PurF disturbance. Moreover, a defective GMP reductase (guaC) in BS110 was found to restore the specific growth rate.
With respect to mutant enzyme activity, to the best of our knowledge, it is the first report of B. subtilis PRPP amidotransferase with D293V, K316Q and S400W mutations to trigger a strong refractory effect on purine nucleotides mediated inhibition. The mutant PurF enzyme activity from strain BS110 suggested that key mutations in PurF severely affected the affinity of purine nucleotides for their binding sites, abolished the inhibitory properties and released PRPP amidotransferase from the feedback regulation. Surprisingly, by assaying the variation trends of in vitro enzyme activities from strain BS110 under different concentrations of four purine nucleotides, the nucleotides ATP and GTP exerted a marked stimulatory effect of PRPP amidotransferase at the lowest concentrations assayed. A possible explanation for this effect could be that ATP and GTP might induce a change in the dimerization status or conformation of the protein, which might contribute to improve stabilization and therefore increased protein activity.
Taken together, we clearly demonstrated that the combination abolishment of regulation in rib operon and purine pathway was sufficient to enhance the production of riboflavin. Moreover, based on intracellular metabolites analysis, the intracellular purine nucleotide concentrations were enhanced in the stepwise gene-targeted deregulation mutant strains. These data showed an activation of purine pathway for riboflavin biosynthesis precursor GTP supply and led to three times riboflavin production increase in shaker flask. Concerning further metabolic engineering of purine pathway, several potential targets are of interest and could be available. As shown in Figure 1B, PRPP synthetase, encoded by prs gene, is subject to feedback inhibition by purine nucleotides, with ADP and GDP being the most effective inhibitors. It has been shown mutated PRS (N120S and L135I) in B. subtilis was desensitized to feedback inhibition by ADP and GDP . And the positive effect on riboflavin production by overexpression of desensitized feedback inhibition PRS mutants have been presented in A. gossypii . Therefore overexpression of deregulated PRPP synthetase should be effective for improvement of purine pathway metabolic flux. Besides, the purA leaky mutation and guaB overexpression may be another useful targets for enhancing riboflavin production in B. subtilis. Last but not the least, fine-tuning expression of genes or mutants involved in purine pathway should not be neglected until all three of titer, productivity and yield have been optimized.
A sequential optimization strategy was applied to deregulate purine pathway of B. subtilis to create genetic diversities and to improve riboflavin production. As a conclusion, these rational deregulation mechanisms to eliminate both transcription repression and feedback inhibition were functional on increasing of the metabolite concentrations of purine pathway, and it also meant significance for the yield of products of purine nucleotides or directly stemming from purine pathway in B. subtilis.
Bacteria strains, medium and chemicals
Bacterial strains and plasmids used in this study
Relevant genotype a
B. subtilis 168
Wide-type strain, trpC2
E. coli DH5α
Standard cloning strain
B. subtilis 168Δupp ribC* ribO* yhcF* yvrH* ywaA*
BS77, P 43 ::ribA
BS77, P 43 ::ribA P 43 ::ribG ΔribP1 ΔribO
BS77, P 43 ::ribA ΔribO
BS77, P 43 ::ribA ΔpurR
BS77, P 43 ::ribA ΔpurR P pur (-10*)
BS77, P 43 ::ribA ΔpurR Δatt
BS77, P 43 ::ribA ΔpurR Δatt P 43 ::purF
BS77, P 43 ::ribA ΔpurR Δatt P pur (-10*)
BS77, P 43 ::ribA ΔpurR Δatt P 43 ::purF D293V K316Q S400W
BS77, P 43 ::ribA ΔpurR Δatt P 43 ::purF K326Q P410W(E. coli)
Cmr, Bacillus cloning vector
Ampr, Cmr, pUC18 containing cat-upp cassette
Ampr, Cmr, containing ribA upstream and downstream flanks under P 43 promoter
Ampr, Cmr, containing ribG upstream and downstream flanks under P 43 promoter
Ampr, Cmr, containing ribO flanks
Ampr, Cmr, containing purR flanks
Ampr, Cmr, containing Ppur(-10*) mutant flanks
Ampr, Cmr, containing att flanks
Ampr, Cmr, containing purF (from B. subtilis) upstream and downstream flanks under P 43 promoter
Ampr, Cmr, containing purF mutant (from B. subtilis) flanks
Ampr, Cmr, containing purF mutant (from E.coli) upstream and downstream flanks under P 43 promoter
The minimal medium and shake cultivation medium for physiological characterizations and fermentation procedure were described as previously reported by Wang et al . Physiological characterizations were carried out in minimal medium and riboflavin production was carried out in shake cultivation medium. To test the riboflavin biosynthetic activity of mutant strains, single colony was transferred into 5 mL Luria-Bertani (LB) medium and incubated at 41°C in a rotatory shaker at 240 rpm for 14 h to prepare the inocula. 2% (v/v) inocula was added aseptically to a 500 mL shake flask containing 50 mL shake cultivation medium. The fermentation was incubated at 41°C in shake flasks at 240 rpm for 72 h. The LBG medium (LB medium with 1% glucose) was used for quantitative RT-PCR analysis. The M medium was used for intracellular metabolite profile analysis . The MM medium containing 10 μm 5FU was used for counter-selection of 5FU resistance colonies . All the experiments were carried out independently in biological triplicates, and the reported results were the average of three replicate experiments.
The plasmids used in this study were shown in Table 3. All primers used in their constructions were shown in Additional file 1: Table S1. This vector pSS as described previously by Shi et al  was used as backbone for all plasmids construction in this study.
For gene in-frame deletion, the upstream and downstream fragments of coding sequence of target gene were amplified by PCR and then inserted into the MCS-I and MCS-II sites of pSS plasmid, respectively. A similar procedure for disruption of purR, att (the attenuator region in 5’-UTR) and ribO was carried out. Taking pSS-purR-FB for example, the purR upstream fragment purR-F was amplified from B. subtilis genome using primers purR-F-U/L and was digested with BglII-XhoI to ligate into the MCS-I of pSS. Then, the purR downstream fragment purR-B was amplified from B. subtilis genome using primers purR-B-U/L and was digested with SalI-BamHI to ligate into the MCS-II to generate pSS-purR-FB. The primers purR-F-L and purR-B-F were designed with the complementary sequence as direct repeat sequence (DR) for counter-selectable cassette eviction. Following the same procedure, plasmids pSS-att-FB and pSS-ribO-FB were constructed.
For purF overexpression, the purF upstream fragment purF-F was firstly amplified from B. subtilis genome using primers purF-F-U/L and was digested with NdeI-XhoI to ligate into the MCS-I of pSS. Second, the strong promoter P 43 and purF gene were both amplified from B. subtilis genome using primers O-P43-U/L and purF-B-U/L, respectively. The primers O-P43-L and purF-B-U were designed as the complementary sequences. These two fragments were then seamlessly joined by splice overlap extension PCR (SOE-PCR) using nested PCR primers Fusion-purF-B-U/L to generate the downstream fragment purF-B, where promoter P 43 was placed upstream of purF gene. Then, the downstream fragment purF-B was digested with PstI-BamHI to ligate into the MCS-II to generate pSS-P43-purF-FB for overexpression of purF. The DR was designed both at the backward primer purF-F-L of the upstream fragment and the forward primer Fusion-purF-B-U of the downstream fragment. Plasmids pSS-P43-ribA-FB, pSS-P43-ribG-FB and pSS-purF*(eco)-FB were constructed following the same procedure. In pSS-purF*(eco)-FB, the upstream fragment was amplified from strain BS106, and the downstream fragment was created by SOE-PCR containing both mutated purF gene from E. coli kindly donated by my colleague Dr. Zhenquan Lin and homologous region from strain BS106.
For markerless gene point mutation, the main procedure of plasmid construction was essentially the same as that of gene deletion expect that the point mutations were introduced by primers. Plasmids pSS-(-10)*-FB and pSS-purF*(bsu)-FB were constructed for markerless mutation of the promoter of pur operon and purF gene of B. subtilis. For construction plasmid pSS-(-10)*-FB, the upstream and downstream fragments were amplified by PCR and then inserted into the MCS-I and MCS-II sites of pSS, respectively. It’s worth noting that the point mutations were simultaneously introduced into the backward primer of the upstream fragment and the forward primer of the downstream fragment. For construction plasmid pSS-purF*(bsu)-FB containing three point mutations, the first point mutation (A878T) was introduced by the backward primer of the upstream fragment, the second (A946C) was introduced by the forward nested PCR primer of the downstream fragment, and the third (CC1199GG) was introduced by the primers that were used for the downstream fragment generated by SOE-PCR.
The construction of mutant strains was based on a mutation delivery system as described previously by Shi et al. . The plasmid pSS-P43-ribA-FB was integrated into BS77 chromosome by the first double-crossover chromosomal transformation and the transformant was selected by chloromycetin. Next, the resulting transformant was cultured in LB liquid medium for 12 h, and then the cells were spread on a MM plate containing 10 μM 5FU. The grown colonies on 5FU MM plate were verified by PCR using primers ribA-F-U and ribA-B-L and by Sanger sequencing to confirm that the upp-cassette was popped out. After the upp-cassette recycling event, the strong promoter P 43 was introduced upstream of ribA locus to generate the ribA overexpression strain, which was denoted as BS89. The rib operon in strain BS89 was constitutively expressed by substitution the native promoter ribP1 and the RFN regulatory element ribO with strong promoter P 43 using plasmid pSS-P43-ribG-FB to generate strain BS93. The RFN regulatory element ribO in strain BS89 was knocked out using plasmid pSS-ribO-FB to yield strain BS96.
The plasmid pSS-purR-FB was used to delete purR in strain BS89, generating BS102. Plasmids pSS-(-10)*-FB and pSS-att-FB were used to mutate the original -10 sequence and the attenuator region in 5’-UTP of pur operon promoter in BS102, individually and in combination, generating strains BS103, BS104 and BS107. Meanwhile, purF was overexpressed in strain BS104 to generate strain BS106 using plasmid pSS-P43-purF-FB. Afterwards, purF in BS106 was markerlessly mutated using plasmid pSS-purF*(bsu)-FB to generate strain BS110, and was markerlessly substituted by the mutated purF gene from E. coli using pSS-purF*(eco)-FB to generate BS111.
Cell growth was monitored by measuring optical density at 600 nm (OD600) with UV-Vis spectrophotometer to monitor the growth of B. subtilis strains. Glucose consumption was quantified by a biosensor (SBA-40E, Shandong, China). For riboflavin measurement, samples were first diluted with 0.05 M NaOH and centrifuged at 16,000 × g for 2 min to remove the cells, the supernatant was then diluted by acetic acid sodium-acetate buffer solution (pH 5.0) to the linear range of the spectrophotometer and the absorbance at 444 nm was recorded . The riboflavin concentration was counted through standard equation which had been validated, Y = (A444-0.0057) × DF/0.0321 [R2 = 0.9968; Y, the riboflavin concentration of sample (mg/L); A444, the value of absorbance at 444 nm; DF, dilution fold; A444 was controlled within the range of 0.3-0.8 by dilution].
Analysis of gene expression by quantitative RT-PCR
Fresh samples of cell cultures, harvested during exponential growth phase in LBG medium, were used to extract total RNA by using RNAprep Pure Cell/Bacteria Kit (Tiangen, Beijing, China) following the manufacturer’s instructions. The cDNA synthesis was prepared using FastQuant RT Kit (with gDNase) (Tiangen, Beijing, China) with random primers. The quantitative RT-PCR was carried out by Light Cycler® 480 II (Roche, Basel, Switzerland) with Real Master Mix (SYBR Green) according to the manufacturer’s instructions as follows. In brief, 100 ng of cDNA was used in a total reaction volume of 20 μl with 0.25 mM of each primer (See Additional file 1: Table S1). The fold change of each transcript in each sample relative to the control was measured in triplicates, normalized to internal control gene rrna and calculated according to the comparative C T method .
Enzyme activity assays
The crude cell extracts were prepared as described previously by Shi et al . PRPP amidotransferase activity was assayed by measurement of the transformation from glutamine into glutamic acid according to the following reaction: Glutamine + PRPP → PRA + Glutamic acid. The standard assay for total PRPP amidotransferase was performed as described previously by Kim et al . The PRPP amidotransferase activity was expressed as nanomoles glutamic acid formed per microgram of protein extract per minute. Total protein concentrations were determined according to the Bradford method .
Intracellular metabolite target analysis
For sampling, 10 mL of cell suspension was harvested during exponential growth phase in M medium using vacuum filtration (-40 to -50 kPa, AP-01P Vacuum Pump, Tianjin Auto Science Co., Ltd.; cellulose nitrate, 0.45 μm pore size. The whole filtration procedure including the washing was completed in less than 30 s.) and washed twice with 2 mL of NaCl solution (2.6%, 20-25°C, the whole filtration procedure including the washing was completed in less than 30 s) . Cells harvested were incubated in 2 mL of -20°C 40:40:20 acetonitrile/methanol/water for metabolite extraction in parallel. Next, the extracts were cooled on ice, transferred into 2 mL tubes, and centrifuged (10 min, 16,000 g, 4°C, PM180R, Italy) to remove cell debris. Then, all samples were lyophilized and redissolved in 200 μL 40:40:20 acetonitrile/methanol/water for further metabolite analysis.
Measurement of intracellular purine metabolites was carried out by liquid chromatography-tandem quadrupole mass spectrometry (LC-MS/MS). Metabolites were firstly separated by aminopropyl column on a Phenomenex Luna NH2 (250 × 4.6 mm, 5 μm) at a flow rate of 1 mL/min. In all cases, 10 μL standard solution or sample was injected. The mobile phase consisted of solvent A (20 mM ammonium acetate + 20 mM ammonium hydroxide in 95:5 water/acetonitrile, pH 9.45) and solvent B (acetonitrile), the metabolites were eluted using a linear gradient of solvent A 98-40% from 0 to 10 min, 40-24% from 10 to 20 min . The metabolites mass spectrometric data were then collected with a Bruker microOTOF-Q II mass spectrometer operated in negative ionization electrospray mode. Compounds were identified in cell extracts using Metabolite Tools™ software and the parameters of compounds, such as retention time, m/z, peak areas, and specific fragmentation pattern, were also identified. Thus, the concentrations of intracellular purine metabolites were quantified based on their standard curves, which were established by plotting the peak areas vs concentrations of each standard solution.
We thank the technical support center of Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences for the help of LC-MS/MS analysis. This work was supported by National Program on Key Basic Research Project (2011CBA00804, 2012CB725203), National Natural Science Foundation of China (NSFC-21206112, NSFC-21176182, NSFC-21390201), National High-tech R&D Program of China (2012AA022103, 2012AA02A702) and the Innovation Foundation of Tianjin University (1308).
- Abbas CA, Sibirny AA: Genetic control of biosynthesis and transport of riboflavin and flavin nucleotides and construction of robust biotechnological producers. Microbiol Mol Biol Rev 2011, 75:321–360.View ArticleGoogle Scholar
- Ledesma-Amaro R, Jiménez A, Santos MA, Revuelta JL: Biotechnological production of feed nucleotides by microbial strain improvement. Process Biochem 2013, 48:1263–1270.View ArticleGoogle Scholar
- Peifer S, Barduhn T, Zimmet S, Volmer DA, Heinzle E, Schneider K: Metabolic engineering of the purine biosynthetic pathway in Corynebacterium glutamicum results in increased intracellular pool sizes of IMP and hypoxanthine. Microb Cell Fact 2012, 11:138.View ArticleGoogle Scholar
- Kappock TJ, Ealick SE, Stubbe J: Modular evolution of the purine biosynthetic pathway. Curr Opin Chem Biol 2000, 4:567–572.View ArticleGoogle Scholar
- Smith JL, Zaluzec EJ, Wery J-P, Niu L, Switzer RL, Zalkin H, Satow Y: Structure of the allosteric regulatory enzyme of purine biosynthesis. Science 1994, 264:1427–1433.View ArticleGoogle Scholar
- Escobar-Henriques M, Daignan-Fornier B: Transcriptional regulation of the yeast gmp synthesis pathway by its end products. J Biol Chem 2001, 276:1523–1530.View ArticleGoogle Scholar
- Sinha SC, Krahn J, Shin BS, Tomchick DR, Zalkin H, Smith JL: The purine repressor of Bacillus subtilis : a novel combination of domains adapted for transcription regulation. J Bacteriol 2003, 185:4087–4098.View ArticleGoogle Scholar
- Saxild HH, Brunstedt K, Nielsen KI, Jarmer H, Nygaard P: Definition of the Bacillus subtilis PurR operator using genetic and bioinformatic tools and expansion of the PurR regulon with glyA , guaC , pbuG , xpt-pbuX , yqhZ-folD , and pbuO . J Bacteriol 2001, 183:6175–6183.View ArticleGoogle Scholar
- Meng LM, Nygaard P: Identification of hypoxanthine and guanine as the co-repressors for the purine regulon genes of Escherichia coli . Mol Microbiol 1990, 4:2187–2192.View ArticleGoogle Scholar
- Weng M, Nagy PL, Zalkin H: Identification of the Bacillus subtilis pur operon repressor. Proc Natl Acad Sci U S A 1995, 92:7455–7459.View ArticleGoogle Scholar
- Cho B-K, Federowicz SA, Embree M, Park Y-S, Kim D, Palsson BØ: The PurR regulon in Escherichia coli K-12 MG1655. Nucleic Acids Res 2011, 39:6456–6464.View ArticleGoogle Scholar
- Mandal M, Boese B, Barrick JE, Winkler WC, Breaker RR: Riboswitches control fundamental biochemical pathways in Bacillus subtilis and Other Bacteria. Cell 2003, 113:577–586.View ArticleGoogle Scholar
- Asahara T, Mori Y, Zakataeva NP, Livshits VA, Yoshida K, Matsuno K: Accumulation of gene-targeted Bacillus subtilis mutations that enhance fermentative inosine production. Appl Microbiol Biotechnol 2010, 87:2195–2207.View ArticleGoogle Scholar
- Zakataeva NP, Romanenkov DV, Skripnikova VS, Vitushkina MV, Livshits VA, Kivero AD, Novikova AE: Wild-type and feedback-resistant phosphoribosyl pyrophosphate synthetases from Bacillus amyloliquefaciens : purification, characterization, and application to increase purine nucleoside production. Appl Microbiol Biotechnol 2012, 93:2023–2033.View ArticleGoogle Scholar
- Chen S, Tomchick DR, Wolle D, Hu P, Smith JL, Switzer RL, Zalkin H: Mechanism of the synergistic end-product regulation of Bacillus subtilis glutamine phosphoribosylpyrophosphate amidotransferase by nucleotides. Biochemistry 1997, 36:10718–10726.View ArticleGoogle Scholar
- Zhou G, Charbonneau H, Colman RF, Zalkin H: Identification of sites for feedback regulation of glutamine 5-phosphoribosylpyrophosphate amidotransferase by nucleotides and relationship to residues important for catalysis. J Biol Chem 1993, 268:10471–10481.Google Scholar
- Zhou G, Smith J, Zalkin H: Binding of purine nucleotides to two regulatory sites results in synergistic feedback inhibition of glutamine 5-phosphoribosylpyrophosphate amidotransferase. J Biol Chem 1994, 269:6784–6789.Google Scholar
- Jiménez A, Santos MA, Pompejus M, Revuelta JL: Metabolic engineering of the purine pathway for riboflavin production in Ashbya gossypii . Appl Environ Microbiol 2005, 71:5743–5751.View ArticleGoogle Scholar
- Matsui H, Kawasaki H, Shimaoka M, Kurahashi O: Investigation of various genotype characteristics for inosine accumulation in Escherichia coli W3110. Biosci Biotechnol Biochem 2001, 65:570–578.View ArticleGoogle Scholar
- Li H, Zhang G, Deng A, Chen N, Wen T: De novo engineering and metabolic flux analysis of inosine biosynthesis in Bacillus subtilis . Biotechnol Lett 2011, 33:1575–1580.View ArticleGoogle Scholar
- Sauer U, Cameron DC, Bailey JE: Metabolic capacity of Bacillus subtilis for the production of purine nucleosides, riboflavin, and folic acid. Biotechnol Bioeng 1998, 59:227–238.View ArticleGoogle Scholar
- Perkins J, Sloma A, Hermann T, Theriault K, Zachgo E, Erdenberger T, Hannett N, Chatterjee N, Williams V II: Rufo Jr G: Genetic engineering of Bacillus subtilis for the commercial production of riboflavin. J Ind Microbiol Biotechnol 1999, 22:8–18.View ArticleGoogle Scholar
- Shi S, Chen T, Zhang Z, Chen X, Zhao X: Transcriptome analysis guided metabolic engineering of Bacillus subtilis for riboflavin production. Metab Eng 2009, 11:243–252.View ArticleGoogle Scholar
- Muchmore CR, Krahn JM, Smith JL, Kim JH, Zalkin H: Crystal structure of glutamine phosphoribosylpyrophosphate amidotransferase from Escherichia coli . Protein Sci 1998, 7:39–51.View ArticleGoogle Scholar
- Kane JF: Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli . Curr Opin Biotechnol 1995, 6:494–500.View ArticleGoogle Scholar
- Hayes CS, Bose B, Sauer RT: Stop codons preceded by rare arginine codons are efficient determinants of SsrA tagging in Escherichia coli . Proc Natl Acad Sci U S A 2002, 99:3440–3445.View ArticleGoogle Scholar
- McNulty DE, Claffee BA, Huddleston MJ, Kane JF: Mistranslational errors associated with the rare arginine codon CGG in Escherichia coli . Protein Expression Purif 2003, 27:365–374.View ArticleGoogle Scholar
- Lithwick G, Margalit H: Hierarchy of sequence-dependent features associated with prokaryotic translation. Genome Res 2003, 13:2665–2673.View ArticleGoogle Scholar
- Qin L, Gong X, Xie J, Jiang D, Cheng J, Li G, Huang J, Fu Y: Phosphoribosylamidotransferase, the first enzyme for purine de novo synthesis, is required for conidiation in the sclerotial mycoparasite Coniothyrium minitans . Fungal Genet Biol 2011, 48:956–965.View ArticleGoogle Scholar
- Van Der Werf MJ, Jellema RH, Hankemeier T: Microbial metabolomics: replacing trial-and-error by the unbiased selection and ranking of targets. J Ind Microbiol Biotechnol 2005, 32:234–252.View ArticleGoogle Scholar
- Hümbelin M, Griesser V, Keller T, Schurter W, Haiker M, Hohmann H, Ritz H, Richter G, Bacher A, Van Loon A: GTP cyclohydrolase II and 3, 4-dihydroxy-2-butanone 4-phosphate synthase are rate-limiting enzymes in riboflavin synthesis of an industrial Bacillus subtilis strain used for riboflavin production. J Ind Microbiol Biotechnol 1999, 22:1–7.View ArticleGoogle Scholar
- Mironov AS, Karelov DV, Solovieva IM, Eremina SY, Errais-Lopes L, Kreneva PA, Perumov DA: Relationship between the secondary structure and the regulatory activity of the leader region of the riboflavin biosynthesis operon in Bacillus subtilis . Russ J Genet 2008, 44:399–404.View ArticleGoogle Scholar
- Shi S, Shen Z, Chen X, Chen T, Zhao X: Increased production of riboflavin by metabolic engineering of the purine pathway in Bacillus subtilis . Biochem Eng J 2009, 46:28–33.View ArticleGoogle Scholar
- Jiménez A, Santos MA, Revuelta JL: Phosphoribosyl pyrophosphate synthetase activity affects growth and riboflavin production in Ashbya gossypii . BMC Biotechnol 2008, 8:67.View ArticleGoogle Scholar
- Wang Z, Chen T, Ma X, Shen Z, Zhao X: Enhancement of riboflavin production with Bacillus subtilis by expression and site-directed mutagenesis of zwf and gnd gene from Corynebacterium glutamicum . Bioresour Technol 2011, 102:3934–3940.View ArticleGoogle Scholar
- Shi T, Wang G, Wang Z, Fu J, Chen T, Zhao X: Establishment of a markerless mutation delivery system in Bacillus subtilis stimulated by a double-strand break in the chromosome. PLoS One 2013, 8:e81370.View ArticleGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402–408.View ArticleGoogle Scholar
- Kim JH, Krahn JM, Tomchick DR, Smith JL, Zalkin H: Structure and function of the glutamine phosphoribosylpyrophosphate amidotransferase glutamine site and communication with the phosphoribosylpyrophosphate site. J Biol Chem 1996, 271:15549–15557.View ArticleGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248–254.View ArticleGoogle Scholar
- Bolten CJ, Kiefer P, Letisse F, Portais J-C, Wittmann C: Sampling for metabolome analysis of microorganisms. Anal Chem 2007, 79:3843–3849.View ArticleGoogle Scholar
- Bennett BD, Yuan J, Kimball EH, Rabinowitz JD: Absolute quantitation of intracellular metabolite concentrations by an isotope ratio-based approach. Nat Protoc 2008, 3:1299–1311.View ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.